Mimedx (MDXG) Cash from Financing Activities (2011 - 2026)
Mimedx (MDXG) posted Cash from Financing Activities of -$13.3 million for Q2 2026, down 413.89% sequentially from -$2.6 million in Q1 2026, and down 1114.26% YoY from $1.3 million in Q2 2025.
Mimedx (MDXG) Cash from Financing Activities (2011 - 2026) Analysis & Trends
Mimedx has reported Cash from Financing Activities for 16 years, with the latest figure at -$13.3 million in Q2 2026.
- Quarterly Cash from Financing Activities fell 1114.26% year-over-year to -$13.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$17.3 million (down 298.37% YoY) and the FY2025 annual result came in at -$5.4 million, up 84.17% from the prior year.
- Cash from Financing Activities retreated to -$13.3 million in Q2 2026 per MDXG's latest filing, from -$2.6 million in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $370000.0 in Q3 2023 and troughed at -$33.5 million in Q1 2024.
- A 5-year average of -$3.6 million and a median of -$491500.0 in 2024 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2022 and 2024: Cash from Financing Activities jumped 200.0% in 2022, then tumbled 836575.0% in 2024.
- Over 5 years, Cash from Financing Activities stood at $66000.0 in 2022, then plunged by 13645.45% to -$8.9 million in 2023, then jumped by 95.53% to -$400000.0 in 2024, then tumbled by 45.75% to -$583000.0 in 2025, then sank by 2178.56% to -$13.3 million in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered -$13.3 million, -$2.6 million, and -$583000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Mimedx | 622.24 Mn | 486.40 Mn | 44.38 Mn | -13.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -13.28 Mn |
| Jun 30, 2026 | -13.28 Mn |
| Mar 31, 2026 | -2.59 Mn |
| Mar 31, 2026 | -2.59 Mn |
| Dec 31, 2025 | -583,000.00 |
| Dec 31, 2025 | -583,000.00 |
| Sep 30, 2025 | -857,000.00 |
| Sep 30, 2025 | -857,000.00 |
| Jun 30, 2025 | -1.09 Mn |
| Jun 30, 2025 | -1.09 Mn |
| Mar 31, 2025 | -2.88 Mn |
| Mar 31, 2025 | -2.88 Mn |
| Dec 31, 2024 | -400,000.00 |
| Dec 31, 2024 | -400,000.00 |
| Sep 30, 2024 | 27,000.00 |
| Sep 30, 2024 | 27,000.00 |
| Jun 30, 2024 | -359,000.00 |
| Jun 30, 2024 | -359,000.00 |
| Mar 31, 2024 | -33.47 Mn |
| Mar 31, 2024 | -33.47 Mn |